Von Hippel Lindau antibody, Internal

GeneTex

Anti-VHL PAb, Internal

9

WB: 0.01-0.03microg/ml. IHC-P: 5microg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

Western Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Polyclonal

0.50 mg/ml

Unconjugated

VHL

von Hippel-Lindau tumor suppressor

elongin binding protein; HRCA1; protein G7; pVHL; RCA1; VHL1; von Hippel-Lindau disease tumor suppressor; von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase

Goat

IgG

von Hippel-Lindau disease tumor suppressor

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]

-20°C or -80°C,2°C to 8°C

12352203